Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955279 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT00955279 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 173 participants.
The verdict
NCT00955279, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients). The purpose of this research study is to determine if ustekinumab or golimumab is safe and to determine its effects (good and bad) on patients with chronic sarcoidosis with pulmonary and/or skin involvement. Patients with pulmonary involvement constitute the primary population for analysis, and patients with skin involvement constitute the secondary population; a patient may be in both populations. The study will be conducted at approximately 40 sites globally.
Interventions
- DRUG Placebo
- DRUG Ustekinumab
- DRUG Golimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955279
The ClinicalTrials.gov registry entry for NCT00955279 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00955279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955279 about?
NCT00955279 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis". This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients). The purpose of this research study is to determine if ustekinumab or golimumab is safe and to determine its effects (good and bad...
What is the current status of trial NCT00955279?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2009-11. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00955279?
The interventions under investigation include: Placebo (DRUG), Ustekinumab (DRUG), Golimumab (DRUG).
Who is sponsoring clinical trial NCT00955279?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.